- Madarosis causes
- Ophthalmic conditions associated with madarosis
- Dermatologic conditions associated with madarosis
- Systemic and endocrine disorders associated with madarosis
- Nutritional disorders
- Parasite infestation
- Chemotherapeutic drugs
- Trichodysplasia spinulosa
- Madarosis signs and symptoms
- Madarosis diagnosis
- Madarosis treatment
Madarosis is a medical term that refers to loss of the eyelashes or eyebrows 1). The term takes its origin from the Greek word “madao” which means to fall off. Loss of the eyelashes alone is also known as milphosis 2). Madarosis can be:
- Unilateral or bilateral
- Incomplete or complete
- Non-scarring or scarring.
In non-scarring madarosis, follicular structures are retained and it is potentially reversible. Scarring madarosis is due to deeper inflammation and fibrosis, and it is more likely to result in permanent lash and hair loss.
Madarosis can be found in both sexes and in any age group but, depending on the underlying cause, it is more common in older people.
Appropriate diagnosis is essential for management. Follicular unit transplantation has been found to be a useful method of treating scarring madarosis and the procedure relevant to eyebrow and eyelash reconstruction has been discussed.
Figure 1. Madarosis
Footnote: Total eyebrow loss in a child with alopecia areata
Eyebrows and eyelashes
The eyebrows are two-arched eminences of skin situated above the orbital regions 3). The hairs of the eyebrows are short, thick. and stiff and are set obliquely. The diameter of eyebrow hair is normally thinner than scalp hair in Asians, and the scalp hair in thinner in Caucasians 4). The eyebrows can be roughly divided into three parts. The medial third is usually below the orbital margin with the hairs in this region oriented vertically. The middle third lies along the orbital margin with hairs oriented obliquely or horizontally. The lateral third usually lies above the orbital margin 5). Eyebrow hair normally tends to be less dense laterally than medially; thus, hair loss from any cause is apt to be more obvious in the lateral portion 6).
The fibers of the orbicularis oculi, corrugators, and frontal part of the occipitofrontalis are inserted into the dermis of the skin underlying the eyebrows. This helps in changing the contour of the eyebrows and consequently facial expression.
Eyelash hairs are usually present in two to three rows, and are short, thick, and curved in appearance. They are set obliquely, anterior to the palpebral muscle. The upper eyelashes are more numerous and curve upward, while the lower eyelashes curve down in order to avoid interlacing during eyelid closure. Eyelash cilia are unique in that they have no erector muscles. Eyelash hairs are oval in all races 7).
The lid appendages and pilosebaceous unit are formed between the third and sixth months of intrauterine life. The development of the eyelashes is apparent initially as proliferation of the surface epithelial cells into the underlying mesenchyme while maintaining an intact basal lamina. Differentiation of the follicles occurs later 8).
Eyelash hair grows at the rate of approximately 0.15 mm per day. They last for 5 to 6 months before falling out. After plucking, a new lash grows in about 8 to 10 weeks 9).
Functions of eyebrows and eyelashes
Eyebrows protect the eyes from sweat that trickles down the forehead. They also protect the bony ridges above the eyes. In addition to the above, the eyebrows play a very important function in facial expression and body language. Eyelashes protect the eyeball from small foreign bodies and irritants and stimulate the closing reflex. Both eyebrows and eyelashes play a very important cosmetic function, and thus contribute greatly to the self esteem of an individual 10).
Madarosis is caused by any process that damages the hair bulb or hair shaft, leading to either temporary or permanent hair loss.
Common causes of madarosis include 11):
- Staphylococcal infection
- Herpes simplex
- Alopecia areata
- Hypothyroidism (typically affecting bilateral outer one-third of eyebrow)
- Atopic dermatitis
- Treatment-induced madarosis, such as that resulting from chemotherapy, radiotherapy, laser treatment, and botulinum toxin injection.
Uncommon causes of madarosis include 12):
- Discoid lupus erythematosus (DLE)
- Lichen planopilaris and frontal fibrosing alopecia
- Different types of skin cancer, such as intraepidermal carcinoma, basal cell carcinoma, squamous cell carcinoma or melanoma
- Infection-related madarosis, such as that resulting from dermatophyte (ringworm) fungus, atypical mycobacteria, leprosy, and human immunodeficiency virus (HIV)
- Vitamin A toxicity
- Drug toxicity (eg, thallium and cocaine)
- Genetic or congenital disorders (eg, ichthyosiform erythroderma, ectodermal dysplasia, cryptophthalmos, and Ehlers–Danlos syndrome)
- Psychiatric causes (eg, trichotillomania and dermatitis artefacta).
Table 1. Madarosis causes
Table 2. Madarosis causes (inherited disorders)
Ophthalmic conditions associated with madarosis
Blepharitis is a chronic primary eyelid inflammation. It is fairly common in occurrence and being a condition with remissions and relapses, results in a decreased quality of life if adequate measures are not taken. Chronic blepharitis is the most common condition associated with madarosis 15). Though there are various ways of classifying blepharitis, the most useful is the one proposed by Wilhelm 16), wherein blepharitis can be classified based on whether there is a predominant involvement of the part of the eyelid anterior to the gray line (anterior blepharitis), or posterior to the gray line (posterior blepharitis). The gray line is an imaginary line dividing the eyelid into an anterior part consisting of the skin and muscle, and a posterior part consisting of the tarsus and conjunctiva.
Anterior blepharitis is usually either staphylococcal or seborrhoeic, and posterior blepharitis refers to any of the varieties of Meibomian gland dysfunction.
The symptoms of anterior blepharitis include itching, burning, foreign body sensation, photophobia, and tearing. The signs include the presence of scurf, collarettes, and sleeves along the lashes 17).
Scurf refers to the scales and greasy crusts that accumulate along the hair shaft and indicates the presence of seborrhea 18). Collarettes are composed of hard fibrinous scales 19) surrounding each individual eyelash. They travel upward along with the growth of the lashes and are indicative of staphylococcal infection. Sleeves or cylindrical dandruff comprise scales that form a cuff around the lash root and are connected with it, in contrast to greasy scales which are not connected to the lash root 20). Sleeves indicate infestation with Demodex folliculorum.
Staphylococcal blepharitis causes lid margin inflammation and folliculitis which destroys the hair follicle resulting in madarosis 21) which is usually non-scarring 22), but occasionally may be scarring, especially if long standing 23). Seborrhoeic blepharitis is very often associated with secondary bacterial infections and can result in madarosis either due to associated staphylococcal infection or due to rubbing caused by itching.
Posterior blepharitis is also known as meibomian gland dysfunction. MacKenzie and Jones 24) used the term “ophthalmia tarsi” to refer to blepharitis due to meibomian gland dysfunction.
Posterior blepharitis is characterized by either excessive foam in the tear film in the hypersecretory type, or plugging of the meibomian orifices in the obstructive type. Expression of the secretions reveals a turbid or toothpaste-like material 25). If there is spillover inflammation of the anterior lid margin, there may be a loss of eyelashes 26).
It may be frequently associated with rosacea, in which case there will be evidence of meibomian gland dysfunction and telangiectatic vessels at the eyelid margin 27).
If a chronic blepharitis does not respond to conventional modes of therapy, then other diseases that may mimic it like discoid lupus erythematosus (DLE) should be considered 28).
Dermatologic conditions associated with madarosis
This manifests in childhood with chronic lower eyelid dermatitis and is often associated with other types of allergic disorders 29). The ocular features are eyelid dermatitis, Dennie-Morgan fold (an infraorbital fold or line due to lid edema in atopic dermatitis), keratitis, and a frequent association with keratoconus and cataracts. Loss of lateral third of eyebrows (Hertoghe sign) is seen in atopic dermatitis due to constant scratching and rubbing 30).
Seborrhoeic dermatitis presents as erythema and scaling of eyebrows. The lids may also show erythematous yellowish fine scales. Edges of lids may show marginal blepharitis. All these features may be associated with madarosis 31). Eyebrow loss is due to scratching as a result of pruritus which is common in seborrhoeic dermatitis 32).
Some of the prominent findings in lamellar ichthyosis are cicatricial lagophthalmos, ectropion of lids, and madarosis 33).
About 10% of patients with psoriasis can have eyelid involvement in the form of blepharitis, psoriatic plaques, and madarosis 34).
Frontal fibrosing alopecia
Postmenopausal frontal fibrosing alopecia, a variant of lichen planopilaris, is a distinct form of scarring alopecia which is described in postmenopausal women. It consists of a receding hairline with scarring associated with a partial or complete loss of eyebrows in most affected individuals. The loss of eyebrows may be the presenting sign; however, the hairline reveals evidence of perifollicular erythema on closer observation. Histologic features are identical to that of lichen planopilaris 35).
Also known as keratosis pilaris atrophicans faciei, it is associated with pinhead follicular plugs with erythema in face along with involvement of and loss of eyebrows 36).
The ocular findings in rosacea are quite frequent and non-specific. They include blepharitis, conjunctivitis, recurrent hordeola and chalazia, rosacea keratitis, and interstitial keratitis. The blepharitis can result in madarosis 37).
The most common cause of hair loss is telogen effluvium. Telogen effluvium is an increased shedding of otherwise normal telogen hairs. It usually occurs in response to systemic disease or altered physiologic states such as severe emotional stress, etc. It can result in a diffuse loss of eyebrow hair 38).
There is pilosebaceous inflammation 39) with both scarring and non-scarring alopecia depending on the degree of inflammation. Most commonly, there is involvement of the head and neck, though widespread involvement is also seen. Eyebrow loss is a prominent finding and may be the presenting symptom when the eyebrow region is involved in the acute benign form of follicular mucinosis 40).
Madarosis has been reported in a case of cutaneous sarcoidosis with nodules and plaques in the face 41).
Systemic and endocrine disorders associated with madarosis
Thyroid hormone receptors were detected in both dermal and epithelial compartments of the human pilosebaceous unit 42). T 4 and T 3 decrease the apoptosis of hair follicles and T 4 prolongs the duration of anagen in vitro 43). Thyroidectomy delays initiation of anagen. Administration of thyroxine advances anagen, initiation of which is however delayed once toxic doses are given. Therefore, ratio of telogen to anagen hairs is increased in hypothyroidism as well as hyperthyroidism 44). Thus, the hair follicles are affected in thyroid disorders, and madarosis is caused due to disturbances in hair cell kinetics. Hypothyroidism is associated with generalized hair loss probably due to coarse, dull, and brittle hair with reduced diameter 45). The eyebrows and eyelashes may also be lost. Loss of lateral one-third of eyebrows known as Hertoghe sign 46) is a characteristic sign of hypothyroidism 47). Some people also refer to it as Queen Anne’s sign 48), after Anne of Denmark whose portrait with shortened eyebrows has been interpreted by some as indicative of the presence of goiter, even though such a fact has not been proved by any known sources of information. Madarosis may even be the presenting sign in hyperthyroidism 49). In hyperthyroidism, there is thinning with breaking off and shortening of hair 50). Madarosis can also occur in hypopituitarism, hypoparathyroidism 51) and hyperparathyroidism. 52).
Madarosis of non-scarring type is commonly seen in alopecia areata which is a hair-specific autoimmune disease associated with patchy loss of hair 53). It presents as round or oval patches of non-scarring hair loss. Madarosis occurs as isolated involvement or as a part of alopecia universalis 54). When alopecia areata involves the eyelashes exclusively, there is rarely involvement of other parts of the body 55). Alopecia areata can involve both the eyelids without scalp involvement also 56). Short exclamation mark hairs are pathognomonic for alopecia areata.
Discoid lupus erythematosus
Discoid lupus erythematosus (DLE) is an autoimmune condition and is the most common form of chronic cutaneous lupus erythematosus 57). Clinically, the lesions start as discoid erythematous patches which then develop into plaques with follicular plugging and scaling. Eyelid findings include blepharitis, lid scarring, entropion, and ectropion. Scaly plaques on the eyelids with loss of hair follicles results in madarosis 58). Numerous studies have reported the mimicking of a chronic blepharitis by DLE 59). A high index of suspicion is necessary in such cases, where the diagnosis is very often delayed by months to years 60). Biopsy with histopathological examination should be done to confirm the diagnosis. Treatment with hydroxychloroquine results in a regrowth of the eyelashes 61).
En coup de sabre
Eyebrow and eyelash loss has been reported in en coup de sabre, a form of localized scleroderma, wherein there is a linear band like scarring in the frontoparietal region 62). These are very often associated with neurological abnormalities 63).
This is a variant of lichen planopilaris which is associated with progressive cicatricial scalp alopecia along with non-scarring loss of pubic, and axillary hair, and lichenoid follicular eruption over the trunk and limbs 64).
Parry-Romberg syndrome is characterized by facial hemiatrophy and is associated with loss of eyebrows and eyelashes 65).
Vogt Koyanagi Harada syndrome
It should be suspected when madarosis is associated with vitiligo and accompanies a granulomatous uveitis 66).
Telogen hairs are shed in chronic marasmus 67) and malnutrition of any type.
Hypoproteinemia 68) causes loss of hair due to premature onset of telogen. Loss of eyebrow hair has been reported due to chronic zinc deficiency in a patient receiving only parenteral nutrition for 2 months 69). Acrodermatitis enteropathica is an inherited disorder of zinc deficiency which shows loss of eyebrows and lashes in addition to cutaneous manifestations 70). Biotin deficiency can result in encephalopathy, neurological disorders, skin desquamation, and loss of eyebrows and eyelashes 71). Iron deficiency may be a possible cause for diffuse telogen hair loss; its exact role however is subject to speculation 72).
Madarosis is the hallmark of lepromatous leprosy. It was reported in 76% of patients with multibacillary leprosy 73). Bilateral symmetric cicatricial madarosis occurs in lepromatous leprosy due to histiocytic infiltration of hair follicles 74). It occurs in multibacillary leprosy after at least 5 to 10 years of untreated disease 75). Loss or atrophy of the eyelashes may follow. Madarosis adds to the cosmetic disfigurement caused by leprosy. Absence of madarosis is a good prognostic sign in long-standing cases 76). Unilateral madarosis may occur in tuberculoid leprosy due to the facial patch in the eyebrow region. In tuberculoid leprosy, madarosis occurs due to granulomatous infiltration of hair follicles leading to their destruction.
Non-scarring eyebrow loss has been reported in secondary syphilis. It is incomplete and has been described as having a moth-eaten appearance. Antisyphilitic treatment has been found to reverse the hair loss 77). Tertiary syphilis can be associated with cicatricial loss of eyebrows 78).
Herpes zoster ophthalmicus causes scarring of the eyelid along with cicatricial ectropion, entropion, trichiasis, madarosis, and poliosis 79). Madarosis has also been described in AIDS 80).
Paracoccidioidomycosis which is seen in Latin America can cause erythematous lesions with madarosis, which can ultimately lead to cicatricial changes and eyelid malpositions 81).
Basak et al. 82) reported 10 cases of periocular tinea which had been misdiagnosed for a long time before the correct diagnosis was made. Only two cases had the central clearing typical of tinea corporis, but all of them were associated with madarosis. There was an improvement in the lesions as well as the madarosis following treatment with topical and systemic antifungals 83).
Eyelash loss can occur with infection with trichophyton and microsporum species 84).
Infestation with the mite D. folliculorum which inhabits the eyelashes is well known. Two species are known to inhabit human beings-D. folliculorum and Demodex brevis 85). It might either be asymptomatic or may cause symptoms of blepharitis. Kemal et al. report an overall prevalence of 27.4% in their study group 86). Gao et al. 87) have reported a 100% prevalence of the mite when there is cylindrical dandruff 88). Patients with demodicosis can develop madarosis.
Madarosis has also been described in phthiriasis of the eyelid. Phthiriasis palpebrarum is the term used to denote infestation of the eyelashes by the pubic louse or Phthirus pubis, also known as crab louse. The parasite is usually transmitted by sexual contact or through fomites. Heavy infestation may result in involvement of axillae, eyebrows, and scalp. When eyebrows and lashes are involved, blue-gray macules or maculae caeruleae may be found on the shoulders, arms, and trunk 89). The louse can be identified under the microscope as having a wide body and strong second and third pair of legs 90).
It is an impulse-controlled disorder characterized by compulsive plucking or breakage of hair 91). The most frequent site of hair pulling is the scalp, but the eyebrows, eyelashes, and pubic hair may also be involved. Trichotillomania manifests in eyelashes and eyebrows as irregular patches of alopecia containing hairs of varying lengths. Inflammation, scarring, and atrophy are conspicuous by their absence. Patients often attempt to conceal their alopecia by cosmetological camouflage. In case of a diagnostic dilemma, histological features such as increased numbers of catagen hairs, pigment casts, and traumatized hair bulbs provide a clue.
Trichoteiromania (hair loss due to repeated rubbing) and trichotemnomania (obsessive shaving of hair) can also result in loss of hair 92).
Tames and Goldenring described a case of bilateral loss of eyebrows and eyelashes in a patient with AIDS-related complex who had smoked crack cocaine. This has been attributed to hot vapors during the process of smoking, and which therefore caused singeing of the brows and lashes. There was a complete reversal once the patient abstained from cocaine 93).
Radiotherapy for ocular tumors
Toxic alopecia occurs when there is a disruption of hair growth in the anagen phase. This usually occurs following chemotherapy and radiotherapy 94). Radiotherapy for various types of ocular tumors, eyelid and choroidal tumors have been reported to produce madarosis 95). Hair loss due to radiation is usually reversible, but may be permanent when the dose of radiation is in the range of 50 to 60 Gy 96).
Retinoids, heparin, anticonvulsants, angiotensin-converting enzyme inhibitors, and androgens can all precipitate telogen hair shedding and madarosis 97).
Other drugs commonly attributed to causing madarosis are miotics, anticoagulants, anti-cholesterol drugs, antithyroid drugs, propranolol, valproic acid, boric acid, and bromocriptine 98). Anticoagulants in high doses have been found to produce loss of scalp, pubic, axillary, and facial hair with loss of eyebrows after a latent period of a few weeks of treatment with dextran and heparin 99). Propranolol can cause diffuse alopecia along with loss of eyebrows due to telogen effluvium 100), usually after three months of therapy 101). Loss of medial aspect of eyebrows can be seen in fetuses exposed to valproic acid 102). Diffuse alopecia including that of eyebrows has been described due to chronic ingestion of mouthwashes containing boric acid. There was complete reversal following stopping the practice 103). Levodopa has been noted to cause severe diffuse alopecia within three months of daily use 104). Hair loss can occur soon after starting topical minoxidil therapy (due to detachment of club hairs following resting hairs reentering anagen), and after cessation of therapy (due to telogen effluvium) 105).
Reversible loss of eyebrows and lashes along with other ocular side effects, possibly due to use of niacin to treat hyperlipidemia, has been reported 106).
Madarosis has been reported as a frequent complication of chemotherapy with docetaxel 107). Garibaldi and Adler 108) described a case that developed madarosis following addition of cetuximab,  and which resolved following discontinuation of the treatment.
Eight of 69 eyes receiving intra-arterial chemotherapy with melphalan for retinoblastoma were found to develop a cutaneous periocular erythema with partial loss of eyelashes 109). Gobin et al. 110) also reported a 12.6% incidence of madarosis following intra-arterial chemotherapy for retinoblastoma. Moti and Fausel 111) described a case of cyclical alopecia areata including the eyebrows and eyelashes after treatment with paclitaxel and carboplatin. Other drugs which have been implicated in hair loss due to anagen effluvium are adriamycin, cyclophosphamide, daunorubicin, epirubicin, etoposide, ifosfamide, irinotecan, topotecan, vindesine, and vinorelbine 112).
Razeghinejad et al. 113) described a case of acute madarosis associated with fever, two days following Measles, Mumps and Rubella (MMR) vaccination. There was associated D. folliculorum in one of the eyelids, and though a causal role is speculated, they attribute the triggering factor to be the MMR vaccination.
Kowing described a patient who developed unilateral madarosis and alopecia following Botulinum A toxin injections in the left masseter and left temporalis muscles for the treatment of left oromandibular dystonia 114). Kass et al. 115) described madarosis following chronic epinephrine therapy.
Hair loss can occur either in acute or chronic hypervitaminosis A. Loss of eyebrows and eyelashes can occur in chronic hypervitaminosis A which can occur in a number of conditions, either due to enthusiastic overdosing or due to intentional prescription of high doses for diseases such as acne, retinal disorders with night blindness, and others 116). The cutaneous manifestations include dry, rough, and scaly skin. Chronic hypervitaminosis A is also becoming increasingly common with use of retinoids for various skin disorders. Acitretin has been noted to cause a high incidence of diffuse hair loss 117). Premature teloptosis may be a prime factor in hair loss induced by retinoids 118).
Thallium poisoning should be suspected in any patient manifesting nervous system and gastrointestinal symptoms along with alopecia. The hair loss affects the scalp, periocular hair, limbs, and sometimes the axillae. Examination of the hair roots under a microscope using polarized light shows distorted anagen roots and several black zones in continued poisoning 119).
Mercury poisoning can occur following use of some cosmetics like bleaching creams, and which result in systemic effects which include diffuse hair loss 120).
Both benign and malignant tumors such as seborrhoeic keratosis, molluscum contagiosum, basal cell carcinoma, squamous-cell carcinoma, sebaceous cell carcinoma, and sclerosing sweat duct carcinoma have been shown to be associated with loss of eyelashes 121). A sebaceous cell carcinoma very often presents as a recurrent chalazion. An associated madarosis (due to lid infiltration and follicle destruction) would help to differentiate the two 122). Tsuji et al. 123) reported a rare case of primary epithelioid hemangioendothelioma of the eyelid associated with madarosis. Primary leiomyoma of the eyelid has been reported with madarosis 124). Kuan described a case of lacrimal gland tumor masquerading as blepharitis with madarosis.
Eyebrow loss with leonine facies has been described in a case of systemic mastocytosis 125).
Cutaneous T-cell lymphoma
The most frequent ocular findings are blepharoconjunctivitis, cicatricial ectropion, meibomianitis, chalazia, and madarosis 126).
A new entity variously called as trichodysplasia spinulosa 127), trichodysplasia of immunosuppression 128) and cyclosporine-induced folliculodystrophy 129) has been described in immunocompromised patients, usually organ transplant recipients on immunosuppression. It involves the development of alopecia predominantly of the face with indurated spinous papules. There is a profound loss of eyebrows 130) and sometimes eyelashes. The histopathologic picture is that of abnormal follicles with hyperkeratotic infundibula and absence of normal hair shafts. The inner root sheath epithelium showed proliferation in the cells and dystrophic trichohyaline granules. Electron microscopy of skin showed presence of intracellular viral particles 131). This entity has lately been reported in immunosuppressive states in patients without organ transplantation such as leukemias and lymphoma 132). van der Meijden et al. 133) described the discovery of a new polyoma virus in a patient with trichodysplasia spinulosa. Histopathological examination can reveal the diagnosis. A recent simple pull-test wherein the spicules can be plucked and examined under the microscope for inner root sheath keratinization has been described 134). Some successful treatments described are cessation of cyclosporine therapy 135) and oral valganciclovir 136) and topical cidofovir 137).
Nezafati et al. 138) described a case of madarosis occurring in a patient who had undergone root canal therapy followed by intrasinus foreign body consisting of root canal filling material. There was a complete regrowth of lashes 6 weeks following surgery for the removal of the foreign body.
Diffuse alopecia including loss of eyebrows has been described in Cronkhite-Canada syndrome which consists of adult onset gastrointestinal polyps, hyperpigmentation of skin, nail dystrophy, onychomadesis, diarrhea, and weight loss 139).
Madarosis signs and symptoms
Madarosis is a medical term that refers to loss of the eyelashes or eyebrows 140). Madarosis is a clinical sign that can occur in various diseases ranging from local dermatological disorders to complex systemic diseases. Madarosis can be scarring or non-scarring depending upon the cause.
Madarosis can be clinically diagnosed based on an adequate history and examination. Useful tests may include:
- Trichoscopy (dermoscopy of hair)
- Skin swabs for bacterial culture and laboratory tests for viral infections, such as polymerase chain reaction (PCR) assays
- Fungal scraping for microscopy and culture
- Skin biopsy
- Blood tests (e.g., thyroid function and vitamin A levels).
Figure 2. Madarosis diagnostic algorithm
The specific treatment recommended for madarosis depends on its underlying cause (eg, antibiotics are recommended for madarosis caused by bacterial infection). Establishing the diagnosis is an important prerequisite for the management of madarosis. For this, madarosis can be broadly classified as scarring and non-scarring. In non-scarring madarosis, generally regrowth of hair occurs after treatment of the primary disorder 142). In disorders such as lepromatous leprosy, though the madarosis is non-scarring, hair regrowth does not occur 143). In such cases, and in cases of scarring madarosis, hair transplant is essential for cosmetic purposes.
Non-specific measures that can be used in madarosis include:
- Cosmetic camouflage
- False eyelashes and eyebrows. Aesthetic camouflage for eyelashes can be achieved with the help of mascara or artificial eyelashes 144)
- Tattooing and dermatography for eyebrows 145)
- Minoxidil solution 146) may be used in the topical treatment of eyebrow loss due to alopecia areata in the form of a 5% solution applied twice daily. Hair growth usually starts by 12 weeks, and it reaches its peak by about 12 months.
- Topical prostaglandin analogues (eg, bimatoprost, latanoprost). Uniocular increase in length, thickness, and pigmentation of the lashes were described by Johnstone in 1997 147) by patients using latanoprost in one eye. There are reports of a response of alopecia of eyelashes to cutaneously administered latanoprost 148), though others report limited success 149). Eyelash growth has also been reported following bimatoprost 0.03% topically to the base of the eyelashes in healthy individuals 150) and in individuals with alopecia areata 151). Bimatoprost ophthalmic solution 0.03% is the only Food and drug administration (FDA)-approved product to safely and effectively enhance the growth of a patient’s own eyelashes 152).
- Hair transplant and eyelash grafting.
Surgical management of madarosis
Surgical reconstruction of eyebrows and eyelashes has its origins in the earlier part of the 20th century. Because of the involvement of the eyebrows in demonstrating various emotions, the restoration of eyebrows is more important cosmetically than scalp hair when there is a loss of both 153).
Various techniques have been described over the years. Nylon implants were used by some people. Now, they are banned in many countries because of complications like scarring and infection. Follicular unit transplantation has been found to give very good results 154) and is now the procedure of choice for most types of hair transplantation.
Follicular unit transplantation for eyebrows
Indications for eyebrow transplant are scarring eyebrow loss, leprosy, and therapy-resistant alopecia areata 155).
The occipital area is usually used for harvesting the donor strip. Softer texture hair for periocular transplantation may be taken from below the nuchal ridge or the lower part of the parietal scalp 156). A 1×4-cm elliptical area of skin is removed. It is then dissected under the stereomicroscope into individual follicular units 157).
Single hair units are preferred as eyebrows consist of only one hair follicular units 158). Alternatively, follicular unit extraction may be done to reduce donor area scarring 159). Single hair unit harvesting using an 18-gauge needle has also been described 160).
The recipient sites in the eyebrow can be conveniently made with 20 to 22-gauge needles parallel to the skin, so that hair grows flat on the skin and does not stick out from the face. About 150 hairs are required for a full eyebrow graft. Poddar et al. 161) described good results with a technique of creating recipient tracks with the erbium yttrium aluminium garnet laser.
Accurate placement of the grafts is necessary to ensure a good cosmetic result. In the medial third, the needles should be inserted parallel to the brow axis 162). The follicles should point toward the tip of the nose and the hairs should converge toward each other in the other two segments, that is, the bulbs in the upper part point toward the forehead and in the lower part toward the other eyebrow 163).
For eyelash grafting, the hair from the follicle is threaded into a French eye needle, which is then inserted into the eyelids and pulled out through the lid margin in the region of the normal position of eyelashes. The follicle will then remain in position in the track created by the needle. The hair may then be trimmed as necessary 164).
Eyelash transplantation may also be done using a strip composite graft from the eyebrow. This method has been advocated because of the similarity between eyebrow and lash hairs 165).
The other techniques available for eyelash reconstruction are follicular unit and reverse follicular unit grafting, double follicular unit grafting, single hair grafting using the sewing technique, or the Choi/KNU implanter 166).
Eyebrow grafts show almost near total success. Eyebrow hair usually starts to grow after three to four months and is fully grown by about six months 167).
Eyelash grafts are less successful due to greater degree of handling. This may be compensated by transplanting a larger number of lashes. However, six one hair grafts per eyelid may often be enough, though there are others who transplant up to 40 hairs per eyelid 168).
Thus, many of the surgical procedures described for eyebrow and eyelash loss have proved to be an effective method of management for scarring madarosis.
References [ + ]
|1, 13, 14, 140, 141, 142, 143.||↵||Kumar A, Karthikeyan K. Madarosis: A marker of many Maladies. Int J Trichol 2012;4:3-18 https://www.ijtrichology.com/text.asp?2012/4/1/3/96079|
|2.||↵||Maguire HC, Hanno R. Diseases of the hair. In: Moschella SL, Hurley HJ, Editors. Dermatology 2 nd ed.Philadelphia: WB Saunders; 1985. p. 1369-86.|
|3, 8.||↵||Bron AJ, Tripathi RC, Tripathi BJ. Wollf’s anatomy of the eye and orbit. London: Arnold; 2001.|
|4.||↵||Gandelman M. A Technique for Reconstruction of Eyebrows and Eyelashes. Semin Plast Surg 2005;19:153-8|
|5.||↵||Standring S. Editor. Gray’s anatomy. The anatomical basis of clinical practice. London: Elsevier; 2008.|
|6.||↵||Anderson BG. Madarosis and Myxedema. JAMA 1966;197:153.|
|7.||↵||Dawber RP, Messenger AG. Hair follicle structure, keratinization and the physical properties of hair. In: Dawber R, editor. Diseases of the hair and scalp. 3 rd ed.London: Blackwell Scientific; 1997. p. 44|
|9.||↵||Vickery SA, Wyatt P, Gilley J. Eye cosmetics. In: Cosmetic Dermatology: Products and Procedures. In; Draelos ZD, Editor. Hoboken, New Jersey: Wiley Blackwell; 2010. p. 191|
|10, 144.||↵||Robbins CR, Editor. Chemical and physical behavior of human hair. 4 th ed.New York: Springer-Verlag; 2002. p. 8.|
|11, 12.||↵||Madarosis. https://dermnetnz.org/topics/madarosis|
|15, 22.||↵||Khong JJ, Casson RJ, Huilgol SC, Selva D. Madarosis. Surv Ophthalmol 2006;51:550-60.|
|16.||↵||Wilhelmus KR. Inflammatory disorders of the eyelid margins and eyelashes. Ophthalmol Clin North Am 1992;5:187-94.|
|17.||↵||Jyotosm JB, Golstein MH. Blepharitis. In: Yanoff M, Duker JS, Editors. Ophthalmology. 3 rd ed.Philadelphia: Mosby Elsevier; 2009. p. 219-21.|
|18.||↵||Starr MB. Infections and hypersensitivity of the eyelids. In: Nesi FA, Lisman RD, Levine MA, Brazzo BG, Gladsone GJ, editors. Smith’s Ophthalmic Plastic and Reconstructive Surgery, 2 nd ed.St Louis, MO: CV Mosby; 1998. p. 485-530.|
|19.||↵||Jackson WB. Blepharitis: Current strategies for diagnosis and management. Can J Ophthalmol 2008;43:170-9.|
|20.||↵||Gao YY, Di Pascuale MA, Li W, Liu DT, Baradaran-Rafii A, Elizondo A. High prevalence of Demodex in eye lashes with cylindrical dandruff. Invest Ophthalmol Vis Sci 2005;46:3094-8.|
|21.||↵||Wright P. The eye and skin. In: Verbov J, Editor. Relationships in dermatology. London: Kluwers Academic Publishers; 1988. p. 35-6.|
|23.||↵||Orentreich DS, Orentreich N. Dermatology of the eyelids, In: Smith BC, Della Rocca RC, Nesi F (editors): Ophthalmic Plastic and Reconstructive Surgery. St. Louis: CV Mosby; 1987. p. 855-906.|
|24.||↵||Mackenzie W, Jones TW. A Practical treatise on the diseases of the eye. 4 th ed. London: Longman, Brown, Green and Longmans; 1854.|
|25.||↵||Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland dysfunction in chronic blepharitis. Cornea 1991;10:277-85.|
|26.||↵||Smith RE, Flowers CW Jr. Chronic blepharitis: A review. CLAO J 1995;21:200-7.|
|27, 37.||↵||Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from Ophthalmology and dermatology clinics. Cornea 2003;22:230-3.|
|28, 57, 60.||↵||Acharya N, Pineda R 2 nd , Uy HS, Foster CS. Discoid Lupus Erythematosus Masquerading as Chronic Blepharoconjunctivitis. Ophthalmology 2005;112: e19-23.|
|29, 32.||↵||James WD, berger TG, Elston DM, Editors. Andrews’ diseases of the skin Clinical dermatology. Philadelphia: Saunders Elsevier; 2006.|
|30, 46.||↵||Saito R, Hori Y, Kuribayashi T. Alopecia in hypothyroidism. In: Kobori T, Montagna W, Editors. Biology of diseases of the hair. Tokyo: University of Tokyo press; 1976. p. 279-85.|
|31.||↵||Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology 2004;208:89-93.|
|33.||↵||Cruz AA, Menezes FA, Chaves R, Pinto Coelho R, Velasco EF, Kikuta H. Eyelid abnormalities in lamellar ichthyoses. Ophthalmology 2000;107:1895-8.|
|34.||↵||Steiner G, Arffa RC. Psoriasis, ichthyosis and porphyria. Int Ophthalmol Clin 1997;37:41-61.|
|35.||↵||Kossard S, Lee MS, Wilkinson B. Postmenopausal frontal fibrosing alopecia: A frontal variant of lichen planopilaris. J Am Acad Dermatol 1997;36:59-66.|
|36.||↵||Clark SM, Mills CM, Lanigan SW. Treatment of keratosis pilaris atrophicans with the pulsed tunable dye laser. J Cutan Laser Ther 2000;2:151-6.|
|38, 101.||↵||Kligman AM. Pathologic dynamics of human hair loss. I. Telogen effluvium. Arch Dermatol 1961;83:175-98.|
|39.||↵||Hempstead RW, Ackerman AB. Follicular mucinosis. A reaction pattern in follicular epithelium. Am J Dermatopathol 1985;7:245-57.|
|40.||↵||Emmerson RW. Follicular mucinosis. A study of 47 patients. Br J Dermatol 1969;81:395-413.|
|41.||↵||Kendrick CG, Brown RA, Reina R, Ford BP, Reed RJ, Nesbitt LT Jr. Cutaneous sarcoidosis presenting as leonine facies. Cutis 2004;73:57-62.|
|42.||↵||Billoni N, Buan B, Gautier B, Gaillard O, Mahé YF, Bernard BA. Thyroid hormone receptor beta1 is expressed in the human hair follicle. Br J Dermatol 2000;142:645-52.|
|43.||↵||van Beek N, Bodó E, Kromminga A, Gáspár E, Meyer K, Zmijewski MA, et al. Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. J Clin Endocrinol Metab 2008;93:4381-8.|
|44.||↵||Rook A. Endocrine Influences on Hair Growth. Br Med J 1965;1:609-14.|
|45.||↵||Comaish JS. The thyroid and hair growth. Semin Dermatol 1985;4:4-8.|
|47.||↵||Leonhardt JM, Heymann WR. Thyroid disease and the skin. Dermatol Clin 2002;20:473-81, vii.|
|48.||↵||Lane Furdell E. Eponymous, anonymous: Queen Anne’s sign and the misnaming of a symptom. J Med Biogr 2007;15:97-101.|
|49, 51.||↵||Jordan DR, Ahuja N, Khouri L. Eyelash loss associated with hyperthyroidism. Ophthal Plast Reconstr Surg 2002;18:219-22.|
|50.||↵||Famuyiwa OO, Bella AF. Thyrotoxicosis in Nigeria. Analysis of a five year experience. Trop Geogr Med 1990;42:248-54.|
|52.||↵||Alonso LC, Rosenfield RL. Molecular genetic and endocrine mechanisms of hair growth. Horm Res 2003;60:1-13.|
|53.||↵||MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG. Guidelines for the management of alopecia areata. Br J Dermatol 2003;149:692-9.|
|54.||↵||Barankin B, Taber M, Wasel N. Successful hair transplant of eyebrow alopecia areata. J Cutan Med Surg 2005;9:162-4.|
|55.||↵||Nanda A, Alsaleh QA, Al-Hasawi F, Al-Muzairai I. Thyroid function, autoantibodies, and HLA tissue typing in children with alopecia areata. Pediatr Dermatol 2002;19:486-91.|
|56.||↵||Yoon KH, Lee SH, Ahn SK, Lee WS. A case of alopecia universalis without involvement of scalp hairs. Yonsei Med J 1995;36:97-101.|
|58.||↵||Ricotti C, Tozman E, Fernandez A, Nousari CH. Unilateral eyelid discoid lupus erythematosus. Am J Dermatopathol 2008;30:512-3.|
|59, 61.||↵||Yaghoobi R, Feily A, Behrooz B, Yaghoobi E, Mokhtarzadeh S. Palpebral involvement as a presenting and sole manifestation of discoid lupus erythematosus. ScientificWorldJournal 2010;10:2130-1.|
|62.||↵||Zannin ME, Martini G, Athreya BH, Russo R, Higgins G, Vittadello F, et al. Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Ocular involvement in children with localised scleroderma: A multi-centre study. Br J Ophthalmol 2007;91:1311-4.|
|63.||↵||Holland KE, Steffes M, Nocton JJ, Schwabe MJ, Jacobson RD, Drolet BA. Linear Scleroderma en coup de sabre with associated neurologic abnormalities. Pediatrics 2006;117;e132-6.|
|64.||↵||Vigilizzo G, Verrini A, Rongioletti F. Familial Lassueur-Graham-Little-Piccardi syndrome. Dermatology 2004;208:142-4.|
|65.||↵||Wartenberg R. Progressive facial hemiatrophy. Arch Neurol Psychiat 1945;54:75-96.|
|66.||↵||Walsh FB, Hoyt WF. Clinical Neuro-ophthalmology. 3 rd ed.Baltimore: Williams and Wilkins Co; 1969. p. 1380-5.|
|67.||↵||Johnson AA, Latham MC, Roe DA. An evaluation of the use of changes in hair root morphology in the assessment of protein-caloric malnutrition. Am J Clin Nutr 1976;29:502-11.|
|68, 120.||↵||Dawber RP, Simpson NB, Barth JH. Diffuse alopecia: Endocrine, metabolic and chemical influences in the follicular cycle. In: Dawber R, Editor. Diseases of the hair and scalp. 3 rd ed.London: Blackwell Scientific; 1997. p. 147.|
|69.||↵||Wexler D, Pace W. Acquired zinc deficiency disease of skin. Br J Dermatol 1977;96:669-72.|
|70.||↵||Neldner KH, Hambidge KM, Walravens PA. Acrodermatitis enteropathica. Int J Dermatol 1978;17:380-7.|
|71.||↵||Dabbagh O, Brismar J, Gascon GG, Ozand PT. The clinical spectrum of biotin-treatableencephalopathies in Saudi Arabia. Brain Dev 1994;16 Suppl:72-80.|
|72.||↵||Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006;54:824-44.|
|73.||↵||Soshamma G, Suryawanshi N. Eye lesions in leprosy. Lepr Rev 1989;60:33-8.|
|74.||↵||Mvogo CE, Bella-Hiag AL, Ellong A, Achu JH, Nkeng PF. Ocular complications of leprosy in Cameroon. Acta Ophthalmol Scand 2001;79:31-3.|
|75.||↵||Hogeweg M. Leprosy and the eye. Community Eye Health 1989;3:2-5.|
|76.||↵||Choyce DP. Ocular leprosy, with reference to certain cases shown. Proc R Soc Med 1955;48:108-12.|
|77.||↵||Ploeg De, Stagnone JJ. Eyebrow alopecia in secondary syphilis. Arch Dermatol 1964;90:172-3.|
|78.||↵||Ozta P, Catal F, Dilmen U. Familial eyebrow diffuse alopecia. J Eur Acad Dermatol Venereol 2005;19:118-9.|
|79.||↵||Holz HA, Espandar L, Moshirfar M. Herpes Zoster Ophthalmicus (HZO). In: Yanoff M, Duker JS, Editors. Ophthalmology. 3 rd ed.Philadelphia: Mosby Elsevier; 2009. p. 222-5.|
|80.||↵||Mansour AM. Adnexal findings in AIDS. Ophthal Plast Reconstr Surg 1993;9:273-9.|
|81.||↵||Cruz AA, Zenha F, Silva JT Jr, Martinez R. Eyelid involvement in paracoccidioidomycosis. Ophthal Plast Reconstr Surg 2004;20:212-6.|
|82, 83.||↵||Basak SA, Berk DR, Lueder GT, Bayliss SJ. Common features of periocular tinea. Arch Ophthalmol 2011;129:306-9.|
|84.||↵||Brown AC. The First Human Hair Symposium. [papers]. New York: Medcom Press; 1974.|
|85, 87, 88.||↵||Gao YY, Di Pascuale MA, Li W, Liu DT, Baradaran-Rafii A, Elizondo A. High prevalence of Demodex in eye lashes with cylindrical dandruff. Invest Ophthalmol Vis Sci 2005;46:3094-8. Back to cited text no. 29|
|86.||↵||Kemal M, Sümer Z, Toker MI, Erdoðan H, Topalkara A, Akbulut M. The Prevalence of Demodex folliculorum in blepharitis patients and the normal population. Ophthalmic Epidemiol 2005;12:287-90.|
|89.||↵||Dawber RP, Fenton DA. Infections and infestations. In: Dawber R, editor. Diseases of the hair and scalp. 3 rd ed.London: Blackwell Science; 1997. p. 438-9.|
|90.||↵||Thappa DM, Karthikeyan K, Jeevankumar B. Phthiriasis palpebrarum. Postgrad Med J 2003;79:102.|
|91.||↵||Smith JR. Trichotillomania: Ophthalmic presentation. Aust N Z J Ophthalmol 1995;23:59-61.|
|92.||↵||Happle R. Trichotemnomania: Obsessive-compulsive habit of cutting or shaving the hair. J Am Acad Dermatol 2005;52:157-9.|
|93.||↵||Tames SM, Goldenring JM. Madarosis from cocaine use. N Engl J Med 1986;314:1324.|
|94, 96.||↵||Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999;341:491-7.|
|95.||↵||Durkin SR, Roos D, Higgs B, Casson RJ, Selva D. Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand 2007;85:240-50.|
|97, 105, 118.||↵||Tosti A, Pazzaglia M. Drug reactions affecting hair: Diagnosis. Dermatol Clin 2007;25:223-31.|
|98.||↵||Roy F, Editor. Ocular syndromes and systemic diseases. New York: Grune and Stratton; 1985. p. 115-7.|
|99.||↵||Tudhope GR, Cohen H, Meikle RW. Alopecia following Treatment with Dextran Sulphate and Other Anticoagulant Drugs. Br Med J 1958;1:1034-7.|
|100.||↵||Martin CM, Southwick EG, Maibach HI. Propranolol induced alopecia. Am Heart J 1973;86:236-7.|
|102.||↵||Clayton-Smith J, Donnai D. Fetal valproate syndrome. J Med Genet 1995;32:724-7.|
|103.||↵||Stein KM, Odom RB, Justice GR, Martin GC. Toxic alopecia from ingestion of boric acid. Arch Dermatol 1973;108:95-7.|
|104.||↵||Marshall A, William MJ. Alopecia and levodopa. Br Med J 1971;2:47.|
|106.||↵||Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol 1995;79:54-6.|
|107.||↵||Cetinkaya A, Hudak D, Kulwin D. Cicatricial Entropion Following Docetaxel (Taxotere) Therapy. Ophthal Plast Reconstr Surg 2011;27: e113-6.|
|108.||↵||Garibaldi DC, Adler RA. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg 2007;23:62-3.|
|109.||↵||Marr B, Gobin PY, Dunkel IJ, Brodie SE, Abramson DH. Spontaneously Resolving Periocular Erythema and Ciliary Madarosis Following Intra-arterial Chemotherapy for Retinoblastoma. Middle East Afr J Ophthalmol 2010;17:207-9.|
|110.||↵||Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial Chemotherapy for the Management of Retinoblastoma: Four-Year Experience. Arch Ophthalmol 2011;129:732-7.|
|111.||↵||Moti SE, Fausel C. Recurring Chemotherapy-Associated Alopecia Areata: Case Report and Literature Review. Pharmacotherapy 2003;23:104-8.|
|112.||↵||Hinds, G, Thomas VD. Malignancy and Cancer Treatment-Related Hair and Nail Changes. Dermatol Clin 2008;26:59-68.|
|113.||↵||Razeghinejad MR, Nowroozzadeh MH, Sharifi M, Monabati A. Acute-onset madarosis following MMR vaccination. J Pediatr Ophthalmol Strabismus 2009;46:123-4.|
|114.||↵||Kowing D. Madarosis and Facial Alopecia Presumed Secondary to Botulinum A Toxin Injections. Optom Vis Sci 2005;82:579-82.|
|115.||↵||Kass MA, Stamper RL, Becker B. Madarosis in chronic epinephrine therapy. Arch Ophthalmol 1972;88:429-31.|
|116.||↵||Oliver TK Jr, Havener WH. Eye manifestations of chronic vitamin A intoxication. AMA Arch Ophthalmol 1958;60:19-22.|
|117.||↵||Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ. Side effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989;20:1088-93.|
|119.||↵||Tromme I, Van Neste D, Dobbelaere F, Bouffioux B, Courtin C, Dugernier T, et al. Skin signs in the diagnosis of thallium poisoning. Br J Dermatol 1998;138:321-5.|
|121.||↵||Jakobiec FA, Zakka FR, Hatton MP. Eyelid basal cell carcinoma developing in an epidermoid cyst: A previously unreported event. Ophthal Plast Reconstr Surg 2010;26:491-4.|
|122.||↵||Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol 2005;50:103-22.|
|123.||↵||Tsuji H, Kanda H, Kashiwagi H, Mimura T. Primary epithelioid haemangioendothelioma of the eyelid. Br J Ophthalmol 2010;94:261-2.|
|124.||↵||Hui JI, Buchser NM, Dubovy SR. Primary eyelid leiomyoma. Ophthal Plast Reconstr Surg 2011;27: e102-3.|
|125.||↵||Chodkiewicz HM, Cohen PR. Systemic mastocytosis-associated leonine facies and eyebrow loss. South Med J 2011;104:236-8.|
|126.||↵||Leib ML, Lester H, Braunstein RE, Edelson RL. Ocular findings in cutaneous T-cell lymphoma. Ann Ophthalmol 1991;23:182-6.|
|127.||↵||Schwieger-Briel A, Balma-Mena A, Ngan B, Dipchand A, Pope E. Trichodysplasia spinulosa-a rare complication in immunosuppressed patients. Pediatr Dermatol 2010;27:509-13.|
|128.||↵||Holzer AM, Hughey LC. Trichodysplasia of immunosuppression treated with oral valganciclovir. J Am Acad Dermatol 2009;60:169-72.|
|129, 135.||↵||Heaphy MR Jr, Shamma HN, Hickmann M, White MJ. Cyclosporine-induced folliculodystrophy. J Am Acad Dermatol 2004;50:310-5.|
|130, 133, 137.||↵||van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC. Discovery of a New Human Polyomavirus Associated with Trichodysplasia Spinulosa in an Immunocompromized Patient. PLoS Pathog 2010;6: e1001024.|
|131.||↵||Haycox CL, Kim S, Fleckman P, Smith LT, Piepkorn M, Sundberg JP, et al. Trichodysplasia spinulosa-a newly described folliculocentric viral infection in an immunocompromised host. J Investig Dermatol Symp Proc 1999;4:268-71.|
|132, 134.||↵||Lee JS, Frederiksen P, Kossard S. Progressive trichodysplasia spinulosa in a patient with chronic lymphocytic leukaemia in remission. Australas J Dermatol 2008;49:57-60.|
|136.||↵||Benoit T, Bacelieri R, Morrell DS, Metcalf J. Viral-associated trichodysplasia of immunosuppression: Report of a pediatric patient with response to oral valganciclovir. Arch Dermatol 2010;146:871-4.|
|138.||↵||Nezafati S, Rahimi S, Mohseni H. Temporary eyelash loss following dental treatment. Int J Oral Maxillofac Surg 2010;39:1142-4.|
|139.||↵||Narendra, Shenoy SD, Bejoy P, Srinivas CR. Cronkhite-Canada Syndrome. Indian J Dermatol 1997;42:102-5.|
|145.||↵||van der Velden EM, Drost BH, Ijsselmuiden OE, Baruchin AM, Hulsebosch HJ. Dermatography as a new treatment for alopecia areata of the eyebrows. Int J Dermatol 1998;37:617-21.|
|146.||↵||Alkhalifah A. Topical and intralesional therapies for alopecia areata. Dermatol Ther 2011;24:355-63.|
|147.||↵||Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-7.|
|148.||↵||Coronel-Pérez IM, Rodríguez-Rey EM, Camacho-Martínez FM. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol 2010;24:481-5.|
|149.||↵||Faghihi G, Andalib F, Asilian A. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol 2009;19:586-7.|
|150.||↵||Cohen JL. Enhancing the Growth of Natural Eyelashes: The Mechanism of Bimatoprost-Induced Eyelash Growth. Dermatol Surg 2010;36:1361-71.|
|151.||↵||Vila TO, Camacho Martinez FM. Bimatoprost in the treatment of eyelash universalis alopecia areata. Int J Trichology 2010;2:86-8.|
|152.||↵||Jones D. Enhanced Eyelashes: Prescription and Over-the-Counter Options. Aesthetic Plast Surg 2011;35:116-21.|
|153, 167.||↵||Avram M. Follicular Unit Transplantation for Male and Female Pattern Hair Loss and Restoring Eyebrows. Ophthalmol Clin N Am 2005;18:319-23.|
|154.||↵||Ergün SS, Sahinoðlu K. Eyebrow transplantation. Ann Plast Surg 2003;51:584-6.|
|155.||↵||Civaº E, Aksoy B, Aksoy HM, Eski M, Yucel K. Hair transplantation for therapy-resistant alopecia areata of the eyebrows: is it the right choice? J Dermatol 2010;37:823-6.|
|156.||↵||Gandelman M. Eyebrow and eyelash transplantation. In: Unger WP, Editor. Hairtransplantation. New York: Marcel Deker; 1995. p. 294.|
|157.||↵||Limmer BL. Elliptical donor stereoscopically assisted micrografting as an approach to further refinement in hair transplantation. Dermatol Surg 1994;20:789-93.|
|158.||↵||Bernstein RM, Rassman WR. Follicular Unit Transplantation. Dermatol Clin 2005;23:393-414, v.|
|159.||↵||Rassman WR, Bernstein RM, McClellan R, Jones R, Worton E, Uyttendaele H. Follicular unit extraction: minimally invasive surgery for hair transplantation. Dermatol Surg 2002;28:720-8.|
|160.||↵||Hirai T, Inoue N, Nagamoto K. Potential use of beards for single-follicle micrografts: convenient follicle-harvesting technique using an injection needle. Ann Plast Surg 2001;47:37-40.|
|161.||↵||Poddar M, Spieth K, Kaufmann R. Er: YAG laser-assisted hair transplantation in cicatricial alopecia. Dermatol Surg 2000;26:1010-4.|
|162.||↵||Pathomvanich D. Anatomical Restoration Surgery of the Eyebrow in Asian. Thai J Surg 2004;25:47-52.|
|163.||↵||Toscani M, Fioramonti P, Ciotti M, Scuderi N. Single Follicular Unit Hair Transplantation to Restore Eyebrows. Dermatol Surg 2011;37:1153-8.|
|164.||↵||Gandelman M. A Technique for Reconstruction of Eyebrows and Eyelashes. Semin Plast Surg 2005;19:153-8.|
|165.||↵||Kasai K. Eyelash reconstruction with strip composite eyebrow graft. Ann Plast Surg 2008;60:649-51.|
|166, 168.||↵||Imagawa K. Eyelash transplant. In: Pathomvanich D, Imagawa K. editors. Hair restoration surgery in Asians. Tokyo: Springer; 2010. p. 223-6.|